HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

HUTCHMED (China) LimitedNASDAQ: HCM

Other Income / Expenses · Q2 FY2025 · quarter ended Jun 2025

Other income / expenses growth accelerates

Q2 FY2025 other income / expenses of $261.12M rose 823.1% year over year, ahead of the +566.3% change in trailing-twelve-month other income / expenses. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +123.8% a year.

Context

  • Other income / expenses amounted to 105.0% of revenue in FY2025, up 90.9 pp from a year earlier.
  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +823.1% holds above the trailing-twelve-month pace of +566.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
$261.12M+0.0% QoQ
Last fiscal yearDec 2025
$577.45M+548.3% YoY
LTMJun 2025
$554.73M+566.3% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+823.1%——
1 year+548.3%——
3-year CAGR+123.8%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
577.45M USD
Year-over-year change
+548.3%
4-year CAGR
+35.1%

Other Income / Expenses vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +566.3% is the highest of 9, against a peer median of -4.8%.
  • Other income / expenses amounts to 92.1% of revenue for HCM, versus a peer median of 10.1%.
HCM Competitors
Other Income / Expenses for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HCMHUTCHMED (China) LimitedLTM Jun 2025$554.73M USD+566.3%+123.8%92.1%
BNTXBioNTech SELTM Jun 2026€260.88M EUR-46.5%—9.9%
INCYIncyte CorporationLTM Jun 2026$130.03M USD-55.4%—2.2%
ZLABZai Lab LimitedLTM Jun 2026$73.27M USD+112.8%—16.3%
EXELExelixis, Inc.LTM Jul 2026$63.96M USD-15.8%+28.1%2.6%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$43.41M USD-19.7%+128.0%19.3%
RCUSArcus Biosciences, Inc.LTM Jun 2026$34M USD+6.3%+33.1%29.1%
ANLAdlai Nortye Ltd.LTM Jun 2024$11.25M USD—-72.8%173.3%
LEGNLegend Biotech CorporationLTM Sep 2026-$1.9M USD+94.1%—0.1%
AAPGAscentage Pharma Group InternationalFY2025-CN¥23.21M CNY+9.1%—4.2%
GMABGenmab A/SLTM Jun 2026-$427.99M USD——10.4%
Peer median (excluding HCM) —-4.8%+30.6%10.1%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.